New York, NY, April 04, 2024 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (Lirum), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today the upcoming presentation of positive data on LX-101, a novel clinical-stage targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held from April 5-10 in San Diego, California.

2024年4月4日，纽约（环球通讯社）--专注于治疗衰弱性疾病的创新临床阶段生物制药公司Lirum Therapeutics，Inc.（Lirum）今天宣布，将于4月5日至10日在加利福尼亚州圣地亚哥举行的2024年美国癌症研究协会（AACR）年会上公布LX-101（一种针对胰岛素样生长因子1受体（IGF-1R）的新型临床阶段靶向治疗）的阳性数据。

Lirum’s data covers clinically-tested LX-101’s potent preclinical anti-tumor activity against variety of adult and pediatric cancers, including cancers of the head and neck and breast as well as certain sarcomas and neuroblastoma, all of which have well-established IGF-1R pathway involvement. In particular, these malignancies have known genetic alterations affecting the IGF-1R pathway and/or high IGF-1R expression tied to poor outcomes.

Lirum的数据涵盖了临床测试的LX-101对多种成人和儿科癌症的有效临床前抗肿瘤活性，包括头颈部和乳腺癌以及某些肉瘤和神经母细胞瘤，所有这些都有完善的IGF-1R途径参与。特别是，这些恶性肿瘤已知影响IGF-1R途径和/或高IGF-1R表达的遗传改变与不良结局有关。

The poster (abstract 1918) will be presented on Monday April 8th from 9:00am to 12:30pm PT in Section 23 of the poster hall and will also be available on the Lirum website (www.lirumtx.com) at the time of its presentation under the Investors and Media tab. Given these promising results and the existing clinical data, Lirum is planning new clinical trials with LX-101 focused on oncologic indications, both pediatric and adult, that carry well-established ties to the IGF-1/IGF-1R pathway.

海报（摘要1918）将于4月8日星期一上午9:00至下午12:30在海报大厅的第23部分发布，并且在发布时也将在Lirum网站（www.lirumtx.com）上的投资者和媒体选项卡下提供。鉴于这些有希望的结果和现有的临床数据，Lirum正在计划使用LX-101进行新的临床试验，重点是儿科和成人的肿瘤适应症，这些适应症与IGF-1/IGF-1R途径有着良好的联系。

Lirum is also developing LX-101 in certain autoimmune diseases, including thyroid dye disease, where IGF-1R has been clinically and commercially validated. About Lirum Therapeutics, Inc.Lirum is an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development and commercialization of novel drug ca.

Lirum还在某些自身免疫性疾病中开发LX-101，包括甲状腺染料疾病，其中IGF-1R已在临床和商业上得到验证。关于Lirum Therapeutics，Inc.Lirum是一家创新的临床阶段生物制药公司，专注于通过新药ca的收购，开发和商业化来治疗衰弱性疾病。